Research progress of mitochondrial toxicity evaluation model for nucleoside drugs
10.12092/j.issn.1009-2501.2020.09.015
- VernacularTitle: 核苷类药物线粒体毒性评价模型的研究进展
- Author:
Pinghu ZHANG
1
Author Information
1. Institute of Translational Medicine, Medical College, Yangzhou University
- Publication Type:Journal Article
- Keywords:
Himalayana Marmota;
Mitochondrial toxicity;
Nucleoside drugs;
Virus
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(9):1059-1065
- CountryChina
- Language:Chinese
-
Abstract:
Antiviral nucleoside drugs represented by zidovudine, lamivudine, telbivudine, ribavirin, etc. have become the first choice drugs for clinical treatment of viral diseases such as AIDS, hepatitis B, herpes. However, the above drugs not only can inhibit virus replication, they can also interfere with the host mitochondrial mtDNA replication through similar mechanisms, leading to mitochondrial toxicity-related adverse reactions. Therefore, both the routine safety evaluation and mitochondrial toxicity evaluation are required for the development of nucleoside drugs. The research progress of mitochondrial toxicity evaluation models of nucleoside drugs are summarized for reference.
